PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Executive Summary
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
You may also be interested in...
‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
US FDA’s RTOR Program Produces Approvals About One Month Sooner Than Priority Review Goal
Novel agents approved under Real-Time Oncology Review posted a median time to approval of seven months, our Pink Sheet RTOR infographic shows, while other RTOR applications had a median 4.5 month approval time.
US FDA’s Real-Time Oncology Review Program Is No Guarantee For Early Approval
Early approvals may not be feasible for all submissions due to specific issues with an application or overall workload considerations, FDA says in a new draft guidance on the RTOR program; agency recommends bundling components of an RTOR application in a maximum of three partial submissions and a final submission.